Therapeutic Antibody Production
Therapeutic Antibody Production - Related Videos
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
0 Views •
Cited by 9 •
2017
This protocol describes the production of a therapeutic antibody in a mammalian expression system. The methods described include preparation of vector DNA, stable transfection and serum-free adaptation of a human embryonic kidney 293 cell line, set up of large scale cultures and purification using affinity chromatography.
02:29
Antibody Production from a Batch Overgrowth Culture of Transfected Mammalian Cells
0 Views •
2025
The video demonstrates a method for producing therapeutic antibodies using stably transfected mammalian cells. Tryptone supplementation stimulates cell division, resulting in overgrowth and supporting a higher antibody yield. The antibody-containing medium is harvested, filtered, and stored for further use.
02:27
Production and Harvesting of Therapeutic Virus-Producing Epithelial Cells
0 Views •
2026
Source: Heidbuechel, J. P., et al. Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo. J. Vis. Exp. (2019).This video demonstrates the process of infecting kidney epithelial cells with genetically engineered viruses for their production and harvesting to study viral replication.
03:22
Production and Purification of Recombinant Antibodies from Mammalian Cells
0 Views •
2025
The video explains the process of producing antibodies in mammalian host cells, from gene expression to secretion. It involves transcription, translation, signal recognition, correct folding, and eventual release into the extracellular medium via secretory vesicles.
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
0 Views •
Cited by 2 •
2017
This protocol describes the in vitro comparison of two key functional characteristics of rituximab: target binding and complement-dependent cytotoxicity (CDC) induction. The methods were employed for a side-to-side comparison between reference rituximab and a rituximab biosimilar. These assays can be employed during biosimilar development or as a quality control in their production.
FAQs
Target selection determines what a therapeutic antibody can recognize and therefore which biological interaction it can influence. An antibody may be chosen for antigen binding that neutralizes a pathogen or toxin, blocks a host-pathogen interaction, or supports immune effector functions. Careful selection is important because retaining specificity links molecular recognition to the intended preventive, diagnostic, or treatment outcome.
After the encoding genes are expressed in cultured mammalian cells, those cells provide the production environment in which antibody components are assembled and secreted. This cellular expression step connects genetic information to a recoverable antibody product. The resulting material can then undergo purification and quality testing, allowing investigators to evaluate whether the produced molecules retain the desired properties.
Therapeutic antibody production must balance several product attributes rather than optimize binding alone. Antigen-binding specificity, molecular stability, and consistent activity all need to be preserved, while impurities and unwanted immune responses are controlled. These requirements matter because a preparation can recognize its target yet still be unsuitable if it is unstable, inconsistent, contaminated, or likely to provoke undesirable immune effects.
Work typically proceeds from selecting an antibody that recognizes the intended antigen to expressing its encoding genes in cultured mammalian cells. The cells assemble and secrete the antibody, after which the product is purified and subjected to quality testing. Each stage supports the next: target recognition guides the design, cellular expression supplies material, and testing checks product suitability.
In infection research, the resulting antibodies can act directly against pathogens or their toxins by neutralizing them. They can also block interactions between a pathogen and host, or guide immune effector functions toward a target. These distinct mechanisms connect antibody design with different intervention strategies, depending on whether the goal is prevention, treatment, or targeted immune activity.
Their antigen specificity can support targeted therapies for immune disorders and diagnostic applications, where recognition of a selected antigen provides the basis for detecting or characterizing a condition. In immunology and infection research, this makes production quality important beyond yield: consistent activity and control of unwanted immune responses influence whether an antibody is useful in its intended setting.